Terns Pharmaceuticals (NASDAQ:TERN) Stock Rating Upgraded by TD Cowen

Terns Pharmaceuticals (NASDAQ:TERN) was upgraded by stock analysts at TD Cowen to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research report on Monday, December 29th. Mizuho upped their target price on Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Wall Street Zen raised shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. William Blair raised shares of Terns Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, November 3rd. Finally, HC Wainwright lifted their price target on Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $58.11.

Terns Pharmaceuticals Trading Down 0.6%

Terns Pharmaceuticals stock opened at $39.23 on Friday. The stock has a fifty day moving average price of $38.25 and a 200 day moving average price of $22.42. The firm has a market capitalization of $4.07 billion, a P/E ratio of -38.09 and a beta of -0.28. Terns Pharmaceuticals has a 52 week low of $1.87 and a 52 week high of $48.26.

Insiders Place Their Bets

In related news, CEO Amy L. Burroughs sold 71,339 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $38.10, for a total value of $2,718,015.90. Following the completion of the sale, the chief executive officer owned 138,976 shares in the company, valued at approximately $5,294,985.60. This represents a 33.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the completion of the sale, the insider directly owned 50,365 shares of the company’s stock, valued at $1,942,578.05. The trade was a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 155,826 shares of company stock worth $5,882,597 over the last quarter. Corporate insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Terns Pharmaceuticals in the fourth quarter valued at approximately $25,000. GAMMA Investing LLC increased its holdings in Terns Pharmaceuticals by 762.4% during the fourth quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock worth $35,000 after buying an additional 770 shares during the last quarter. Engineers Gate Manager LP acquired a new position in Terns Pharmaceuticals during the second quarter worth approximately $41,000. iA Global Asset Management Inc. bought a new stake in Terns Pharmaceuticals in the 4th quarter valued at $43,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Terns Pharmaceuticals during the 2nd quarter worth about $46,000. Institutional investors own 98.26% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.